Reports
Reports
The global primary cells market attained a value of about USD 1.24 billion in 2023. The market is further expected to grow at a CAGR of 11.5% during the forecast period of 2024-2032 to reach nearly USD 2.36 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The consistent growth in the global market for primary cells can be associated with the rising occurrence of cancers worldwide. Primary cells are utilised for the discovery of cancer cells and drug screening owing to effectiveness over cell lines, which is aiding the market growth. Furthermore, primary cells are further used for extensive research activities carried out for the development of relevant therapies and techniques, including cell therapies and regenerative therapies, to treat patients with cancer.
Since cancer is recognised as the leading cause of fatalities, governments and private institutes all around the world are rapidly investing in advanced healthcare technologies for effective cancer treatment, hence providing impetus to the market growth of primary cells.
Primary cells refer to cells taken directly from living tissues of animals or humans and are then processed to establish them for use in relevant cell therapies.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of origin, the market can be segmented into:
The market, based on cell type, can be categorised into:
Hepatocytes can be subdivided into cryopreserved hepatocytes and fresh hepatocytes.
Based on end user, the market can be divided into:
The EMR report looks into the regional markets of primary cells like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global market for primary cells is being rapidly driven by robust investments into the research and development (R&D) activities for the development of effective therapies where primary cells can be used to treat several immunodeficiency disorders. Owing to the growth in biotechnology and biopharmaceutical sectors, medical researchers are constantly working on utilising primary cells from an animal or human tissue for the treatment of malignant cancers. Furthermore, the use of patient-derived specimens in innovative preclinical technologies, such as 3D cell cultures, due to their accurate outcomes, is furthering the market growth of primary cells. Moreover, the use of human primary cells is progressively becoming a preferred choice for understanding the effects of cancer cells on human body without being subjected to animal cells. This is contributing to the overall market growth of primary cells.
The report presents a detailed analysis of the following key players in the global primary cells market, looking into their capacity, market share, and latest developments like capacity expansions, plant turnabouts and mergers and acquisitions:
The comprehensive report looks at the micro and macro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of the Porter’s Five Forces Model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Origin, Cell Type, End User, Region |
Breakup by Origin | Animal Primary Cells, Human Primary Cells |
Breakup by Cell Type | Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, Renal Cells, Others |
Breakup by End User | Life Science Research Companies, Research Institutes |
Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | Merck KGaA, Axol Bioscience Ltd., Cell Biologics, Inc., Lonza Group AG., PromoCell GmbH, Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Primary Cells Market Analysis
8.1 Key Industry Highlights
8.2 Global Primary Cells Historical Market (2018-2023)
8.3 Global Primary Cells Market Forecast (2024-2032)
8.4 Global Primary Cells Market by Origin
8.4.1 Animal Primary Cells
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Human Primary Cells
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.5 Global Primary Cells Market by Cell Type
8.5.1 Dermatocytes
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Gastrointestinal Cells
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Heart Cells
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Hematopoietic Cells
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Hepatocytes
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
8.5.5.3 Breakup by Type
8.5.5.3.1 Cryopreserved Hepatocytes
8.5.5.3.1.1 Historical Trend (2018-2023)
8.5.5.3.1.2 Forecast Trend (2024-2032)
8.5.5.3.2 Fresh Hepatocytes
8.5.5.3.2.1 Historical Trend (2018-2023)
8.5.5.3.2.2 Forecast Trend (2024-2032)
8.5.6 Lung Cells
8.5.6.1 Historical Trend (2018-2023)
8.5.6.2 Forecast Trend (2024-2032)
8.5.7 Musculoskeletal Cells
8.5.7.1 Historical Trend (2018-2023)
8.5.7.2 Forecast Trend (2024-2032)
8.5.8 Renal Cells
8.5.8.1 Historical Trend (2018-2023)
8.5.8.2 Forecast Trend (2024-2032)
8.5.9 Others
8.6 Global Primary Cells Market by End User
8.6.1 Life Science Research Companies
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Research Institutes
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.7 Global Primary Cells Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Primary Cells Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Primary Cells Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Primary Cells Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Primary Cells Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Primary Cells Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Merck KGaA
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Axol Bioscience Ltd.
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Cell Biologics, Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Lonza Group AG.
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 PromoCell GmbH
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Primary Cells Market: Key Industry Highlights, 2018 and 2032
2. Global Primary Cells Historical Market: Breakup by Origin (USD Million), 2018-2023
3. Global Primary Cells Market Forecast: Breakup by Origin (USD Million), 2024-2032
4. Global Primary Cells Historical Market: Breakup by Cell Type (USD Million), 2018-2023
5. Global Primary Cells Market Forecast: Breakup by Cell Type (USD Million), 2024-2032
6. Global Primary Cells Historical Market: Breakup by End User (USD Million), 2018-2023
7. Global Primary Cells Market Forecast: Breakup by End User (USD Million), 2024-2032
8. Global Primary Cells Historical Market: Breakup by Region (USD Million), 2018-2023
9. Global Primary Cells Market Forecast: Breakup by Region (USD Million), 2024-2032
10. North America Primary Cells Historical Market: Breakup by Country (USD Million), 2018-2023
11. North America Primary Cells Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Europe Primary Cells Historical Market: Breakup by Country (USD Million), 2018-2023
13. Europe Primary Cells Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Asia Pacific Primary Cells Historical Market: Breakup by Country (USD Million), 2018-2023
15. Asia Pacific Primary Cells Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Latin America Primary Cells Historical Market: Breakup by Country (USD Million), 2018-2023
17. Latin America Primary Cells Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Middle East and Africa Primary Cells Historical Market: Breakup by Country (USD Million), 2018-2023
19. Middle East and Africa Primary Cells Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Global Primary Cells Market Structure
The global primary cells market attained a value of nearly USD 1.24 billion in 2023.
The market is projected to grow at a CAGR of 11.5% in the forecast period of 2024-2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 2.36 billion by 2032.
The market is being primarily driven by the rising prevalence of chronic and life-threatening disorders, such as cancers.
Rising government and private investments into the healthcare sector for the development of novel techniques using primary cells for the treatment of cancer is furthering the market growth.
The major regional markets for primary cells are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
The segmentations based on origin of primary cells are animal primary cells and human primary cells.
The significant cell types of primary cells include dermatocytes, gastrointestinal cells, heart cells, hematopoietic cells, hepatocytes, lung cells, musculoskeletal cells, and renal cells, among others.
The major end users of primary cells are life science research companies and research institutes.
The major players in the industry are Merck KGaA, Axol Bioscience Ltd., Cell Biologics, Inc., Lonza Group AG., and PromoCell GmbH, among others.
The global primary cells market attained a value of about USD 1.24 billion in 2023, driven by rising prevalence of cancers. Aided by large scale investment into the healthcare sector, the market is expected to grow at a CAGR of 11.5% in the forecast period of 2024-2032 to reach nearly USD 2.36 billion by 2032.
EMR’s meticulous research methodology delves deep into the market covering the macro and micro aspects of the industry. On the basis of origin, the market can be divided into animal primary cells and human primary cells. The market, based on cell type, can be broadly categorised into dermatocytes, gastrointestinal cells, heart cells, hematopoietic cells, hepatocytes, lung cells, musculoskeletal cells, and renal cells, among others. Based on end user, the market can be segmented into life science research companies and research institutes. The major regional markets for primary cells are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa. The key players in the industry are Merck KGaA, Axol Bioscience Ltd., Cell Biologics, Inc., Lonza Group AG., and PromoCell GmbH, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.